- Home
- UTL vs VSTM Comparison
UTL vs VSTM Comparison
Compare UTL & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UTL | VSTM |
|---|---|---|
| Founded | 1984 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 899.9M | 723.8M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | UTL | VSTM |
|---|---|---|
| Price | $50.58 | $6.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $55.00 | $13.38 |
| AVG Volume (30 Days) | 107.7K | ★ 2.1M |
| Earning Date | 02-09-2026 | 11-04-2025 |
| Dividend Yield | ★ 3.57% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.85 | N/A |
| Revenue | ★ $502,000,000.00 | $13,379,000.00 |
| Revenue This Year | $5.98 | $208.54 |
| Revenue Next Year | $7.76 | $251.40 |
| P/E Ratio | $17.70 | ★ N/A |
| Revenue Growth | 1.03 | ★ 33.79 |
| 52 Week Low | $44.61 | $4.01 |
| 52 Week High | $59.99 | $11.25 |
Technical Indicators
Market Signals| Indicator | UTL | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 63.52 | 36.02 |
| Support Level | $48.17 | $6.68 |
| Resistance Level | $50.82 | $7.26 |
| Average True Range (ATR) | 0.89 | 0.59 |
| MACD | 0.20 | -0.04 |
| Stochastic Oscillator | 91.18 | 10.29 |
Price Performance
Historical ComparisonAbout UTL UNITIL Corporation
Unitil Corp is a holding company, through its subsidiaries it is engaged in the local distribution of electricity and natural gas throughout its service territories in the states of New Hampshire, Massachusetts, and Maine. The Company has two operating and reportable segments: Utility Electric Operations and Utility Gas Operations. Majority of revenue is gained from Electric Segment.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.